Teva falls on Copaxone data

Teva (NASDAQ:TEVA) was off $4.02 to $43.18 on Monday after top-line data from the Phase III FORTE trial in 1,155 relapsing-remitting multiple sclerosis (RRMS) patients showed that the 40 mg dose of Co...